ArticleInternational journal of environmental research and public health2020
Evaluation of Prevalence of the Sarcopenia Level Using Machine Learning Techniques: Case Study in Tijuana Baja California, Mexico.
Article in International journal of environmental research and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Identifying risk factors for sarcopenia using machine learning: insights from multimodal data.European geriatric medicine · 2025Article
- Development and validation of machine learning models for classifying cancer-related sarcopenia using Kinect-based mixed-reality exercises in breast cancer survivors.Translational cancer research · 2025Article
- Anthropometric Measurements for Predicting Low Appendicular Lean Mass Index for the Diagnosis of Sarcopenia: A Machine Learning Model.Journal of functional morphology and kinesiology · 2025Article
- A systematic review of Machine Learning and Deep Learning approaches in Mexico: challenges and opportunities.Frontiers in artificial intelligence · 2024Review
- Machine Learning Applications in Sarcopenia Detection and Management: A Comprehensive Survey.Healthcare (Basel, Switzerland) · 2023Article
- Use machine learning to help identify possible sarcopenia cases in maintenance hemodialysis patients.BMC nephrology · 2023Article
- Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020).Journal of clinical medicine · 2023Article
- Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.Journal of rehabilitation medicine · 2021Article
- Obstructive sleep apnea syndrome-related hypertension and sarcopenia: a brief glance on the renin-angiotensin-aldosterone system.Sleep & breathing = Schlaf & Atmung · 2021Article
- Sarcopenia, Exercise and Quality of Life.International journal of environmental research and public health · 2021Article
- Sarcopenia and COVID-19: A Manifold Insight on Hypertension and the Renin Angiotensin System.American journal of physical medicine & rehabilitation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The article presents a study based on timeline data analysis of the level of sarcopenia in older patients in Baja California, Mexico. Information was examined at the beginning of the study (first event), three months later (second event), and six months later (third event). Sarcopenia is defined as the loss of muscle mass quality and strength. The study was conducted with 166 patients. A total of 65% were women and 35% were men. The mean age of the enrolled patients was 77.24 years. The research included 99 variables that consider medical history, pharmacology, psychological tests, comorbidity (Charlson), functional capacity (Barthel and Lawton), undernourishment (mini nutritional assessment (MNA) validated test), as well as biochemical and socio-demographic data. Our aim was to evaluate the prevalence of the level of sarcopenia in a population of chronically ill patients assessed at the Tijuana General Hospital. We used machine learning techniques to assess and identify the determining variables to focus on the patients' evolution. The following classifiers were used: Support Vector Machines, Linear Support Vector Machines, Radial Basis Function, Gaussian process, Decision Tree, Random Forest, multilayer perceptron, AdaBoost, Gaussian Naive Bayes, and Quadratic Discriminant Analysis. In order of importance, we found that the following variables determine the level of sarcopenia: Age, Systolic arterial hypertension, mini nutritional assessment (MNA), Number of chronic diseases, and Sodium. They are therefore considered relevant in the decision-making process of choosing treatment or prevention. Analysis of the relationship between the presence of the variables and the classifiers used to measure sarcopenia revealed that the Decision Tree classifier, with the Age, Systolic arterial hypertension, MNA, Number of chronic diseases, and Sodium variables, showed a precision of 0.864, accuracy of 0.831, and an F1 score of 0.900 in the first and second events. Precision of 0.867, accuracy of 0.825, and an F1 score of 0.867 were obtained in event three with the same variables. We can therefore conclude that the Decision Tree classifier yields the best results for the assessment of the determining variables and suggests that the study population's sarcopenia did not change from moderate to severe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.